That is very important, because the method a protein in the human body folds figures out if a pharmaceutical will have the ability to bind to that protein and be efficient. In other words, we have to understand how these proteins fold if we want a drug to work. Historically, this has actually been a trial-and-error procedure (exponential growth). However now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it much easier to create drugs that do what they're developed to do. This was a breakthrough practically no one saw. However it's going to have profound ramifications for treating disease. I predict that Alpha, Fold will be 98% accurate by the end of 2021.
And, obviously, there will be lots of financial investment chances in this area, too. Moving subjects It's going to be a good year for bitcoin. I'm bullish on it in 2021 (artificial intelligence). That stated, I still think bitcoin will continue to be volatile. We're close to all-time highs. I wouldn't be shocked if it pulled back possibly significantly prior to going greater - united arab emirates. I have actually been covering bitcoin for a long time now. One of the first research study reports I ever released was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary suggestion, I entitled my report "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time. We were mainly educating readers. However that's not the big concern anymore. Now we're seeing institutional cash lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some little, specific niche enterprise. Mass, Mutual is a relied on 170-year-old institution. So think about that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
And that's a big factor I'm bullish on it this year. biotech stocks. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus offer forecast 2020 was a record year for IPOs. 552 U.S. business went public the most in more than 20 years. These business raised an overall of $172 billion. That's an all-time high beating the previous annual record by 43%. I anticipate 2021 will be another record year in IPOs. There are so numerous excellent personal business on the verge of striking the general public markets And I've been working on a brand-new method for you to invest even before these companies go public.
This opportunity has been constructing over the last couple of years. I can't wait to tell you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the details. Go right here to book your area for complimentary.
Emma Walsh here, handling editor of the Diary. Regular Journal readers know that tech isn't our normal beat (future report). And when it pertains to tech investing, we leave it to the specialists. Thankfully, we have a number of such specialists in our Rolodex. Our associate Jeff Brown will be familiar to our long time readers. He is one of the most accomplished tech investing specialists we understand (last year). In reality, he had numerous triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the huge image and forecast what's just around the corner.
That includes things like 5G networks, biotech, expert system, and much more. These trends are experiencing rapid growth and producing extraordinary opportunities for investors. I wish to make sure all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see being available in the next 12 months Our new 5G (fifth-generation) wireless networks are a subject I have actually been covering for years now. tech predictions. But regardless of what lots of readers may think, this is a trend that's simply getting begun. Despite the fact that the COVID-19 pandemic interfered with supply chains in 2015, a remarkable 250 million 5G-enabled devices were still sold.
And all of this eventually caused Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (artificial intelligence). Losing 2 months of manufacturing and sales really impacts how many 5G gadgets are offered in the calendar year. When you think about all of that, offering 250 million systems is amazing. More significantly, the delays triggered by the pandemic created a load of bottled-up need. Which need is now going to be pressed into 2021. In fact, I forecast that more than 500 million 5G devices will be delivered in 2021 - jeff brown prediction for 2021. And that's not my only 5G prediction When I have actually spoken about 5G in the past, I've described its 3 various stages.
In Stage 2, 5G devices go on sale. 5G phones and other products begin to reach customers. And in Phase Three, 5G services start to be offered (jeff brown investment prediction). That's when we start to see applications operating on 5G networks. Consider things like enormous multiplayer video games over a cellphone. That's not possible with 4G. It will be with 5G. And my 2nd 5G prediction for 2021 is that we will start Phase 3 by this summer. This begins something of a virtuous cycle: The majority of people don't actually care about the technology. However they will care if there are exciting applications that can only be accessed with a 5G phone.
That causes more 5G apps being established. In truth, 5G is going to open up a suite of amazing applications: self-driving automobiles, the Web of Things, robotic surgery, and more. All of these innovations need 5G. The financial investment opportunities moving forward will be massive. Stepping far from 5G, the next crucial innovation I foresee in 2021 is CRISPR hereditary modifying. CRISPR stands for "clustered regularly interspaced brief palindromic repeat." It's a mouthful. However it is among the most exciting advancements in biotechnology. At a high level, CRISPR is an innovation that can edit our hereditary makeup as if it were software application.
The program can crash or not function properly. CRISPR utilizes a comparable concept however with our hereditary code. "Typos" in our genome can lead to illness. CRISPR can correct these "typos." For several years, CRISPR was primarily a niche innovation that wasn't well understood. And throughout that time, there were actually just three business operating in this space. But things are changing. CRISPR is no longer simply theoretical. We're seeing real results. We're dealing with illness and seeing that this innovation just works. And as an outcome, a "2nd crop" of early-stage CRISPR companies is going public and delivering amazing returns. This whole industry is effectively a greenfield chance.
There's room for many companies to exist in this area. future report review. And there will be more. That's my forecast for CRISPR in 2021. I anticipate that two or 3 more hereditary modifying business will hold their IPOs. Sticking with biotechnology, we are seeing remarkable things happening at the merging of biotech and artificial intelligence (AI). Google's AI subsidiary, Deep, Mind, simply announced at the end of 2020 that its latest Alpha, Fold software application can precisely forecast the folding of a protein based exclusively on its amino acid sequence with 92. 4% accuracy. That's important since the method a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and be reliable.
Historically, this has been a trial-and-error procedure. But now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it much easier to produce drugs that do what they're designed to do. And here's my next forecast. I forecast that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one but a number of drug therapies produced using this innovation. This was one of those developments that nearly no one observed. But it's going to have extensive ramifications for curing disease. And, obviously, there will be a lot of investment opportunities in this space, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be surprised if it pulled back maybe significantly prior to going higher. I've been covering bitcoin for a long time now. One of the first research reports I ever released was on bitcoin - jeff brown latest prediction. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anybody who followed my suggestion. However at the time of that preliminary recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the conversation was at the time.
But nobody is asking that concern any longer. Now, we're seeing institutional money finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. jeff brown 2021 stock predictions. Mass, Mutual is a 150-year-old institution. So believe about that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more bonus offer prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and declares the info is up to date since February 2021, however we might not separately verify this claim. Provided Jeff Brown's past, he likely has a significant net worth, however we can't hammer down a precise figure at this minute. Brown is best known for his sage-like ability to pick winning innovation stocks. He spent more than 25 years investigating technology companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience provides him an excellent point of view on the market. He's always on the hunt for new opportunities, and he shares much of his best picks in the Near Future Report.
That's full marks, but it's not absurdly reasoned. Brown has an exceptional reputation as a stock-picker, and he effectively anticipated some of the greatest financial events of the past twenty years. Although he doesn't appear to launch his choices to the public, the service's success is a direct sign of Brown's stock-picking expertise. Nobody on Wall Street gets it ideal each time, but Jeff Brown's accurate forecasts have actually earned him legions of dedicated fans. That states a lot about his capability. The Near Future Report is published by Brownstone Research study, a prominent monetary research publisher. Brownstone Research study offers numerous research services with a variety of specializations - social media.
The business is likewise associated with Bonner & Partners, another well-respected research study publisher - jeff brown biotech picks. On its site, Brownstone says its mission is to offer retail investors with professional-grade research: "For too long, the finest investment research study has not been offered to individual investors. It has been normally reserved for financial investment banks, hedge funds, personal equity, and high-net-worth customers. exponential tech investor. The objective of Brownstone Research study is to make that kind of exclusive research offered to any financiers looking to gain an edge in the markets. The objective is easy to deliver distinct and successful financial investment research found no place else." -Brownstone Research website excerpt from the Jeff Brown is the founder of Brownstone Research study, and he also serves as the company's Chief Financial investment Analyst.
With Brown directing the ship, Brownstone Research is a powerhouse publisher with lots to offer its clients. After decades of constant success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a family name throughout most of America. If you know even a little bit about the market, you know that he has a reputation as a King Midas of sorts. jeff brown biotech genome sequencing. Everything he touches relies on gold! Jeff is well conscious of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next big job.
In truth, Brown thinks S.A.V. jeff brown top stock pick 2021. might be "the greatest trend of the 2020s, and he's not alone. Have a look at these quotes from other well-known S.A.V. bulls: Elon's next huge act will be marrying two advanced innovations: expert system and electric vehicles. Musk hopes the combination will help him establish the first fully-autonomous, self-driving cars and trucks ever. It's absolutely nothing except the vehicle industry's Holy Grail. As you understand, electric automobiles and self-driving car stocks have been big this year, however the Wall Street machine has actually approved buzz without much concrete result. Regardless of an extreme increase in competition over the previous couple of years, Brown still believes Musk has the very best opportunity of putting everything together.
tech could be the magic string that connects all of it together. S.A.V. represents Shared Autonomous Car, and it might be the future of transportation. Basically, this technology would enable you to lease your automobile as an autonomous, self-driving taxi when you're not using it. You just leave the automobile and press a button on an app that informs the automobile to "join the fleet." Next thing you know, you're relaxing on your sofa while your cars and truck shuttles ride-sharers around town. Most importantly, you get to keep a hefty piece of the earnings. It sounds ridiculous, however it could be closed than you believe.